<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01418742</url>
  </required_header>
  <id_info>
    <org_study_id>GMIHO-010/2009</org_study_id>
    <nct_id>NCT01418742</nct_id>
  </id_info>
  <brief_title>SKIP - A Double-blind Placebo-controlled Randomized Multicenter Trial of Skin Toxicity Treatment</brief_title>
  <official_title>SKIP - A Double-blind Placebo-controlled Randomized Multicenter Phase II Trial of Skin Toxicity Treatment in Subjects With Advanced or Metastatic Colorectal Carcinoma Receiving Panitumumab</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gesellschaft fur Medizinische Innovation – Hamatologie und Onkologie mbH</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>ClinAssess GmbH</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Gesellschaft fur Medizinische Innovation – Hamatologie und Onkologie mbH</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Skin toxicity treatment in patients with advanced or metastatic colorectal cancer (mCRC) and
      non-mutated (wild-type) KRAS treated with panitumumab monotherapy after failure of
      fluoropyrimidine-, oxaliplatin-, and irinotecan-containing chemotherapy regimens.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Because of their frequency and severity panitumumab associated skin toxicities affect
      patients' quality of life and thus threaten patients' compliance to therapy. There is an
      urgent need for evidence-based treatment recommendations for the prevention and management of
      panitumumab -associated skin toxicities.

      The study aims to compare the efficacy and safety of a manageable preemptive treatment with
      oral doxycycline in combination with a supportive topical regimen containing erythromycin
      cream (2 %) over duration of 12 weeks on the occurrence and grade of panitumumab induced skin
      toxicities in a double-blind, controlled randomized setting. Basic skin treatment with or
      without doxycycline will be discontinued at the end of study treatment after 12 weeks or
      until a value of 6-10 is observed on the visual analogue scale (VAS), whichever is sooner.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Recruitement did not meet expectations. Prev. differentiation of RAS-wild-type and mutated RAS
    are not in accordance with the scientific rank anymore.
  </why_stopped>
  <start_date>August 2011</start_date>
  <completion_date type="Actual">May 2013</completion_date>
  <primary_completion_date type="Actual">May 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time until unblinding of skin therapy allocation (basic skin treatment with or without doxycycline) due to insufficient efficacy (i.e. unbearable skin toxicity, measured by patient's allocating point 6 through 10 on a visual analogue scale)</measure>
    <time_frame>30 month</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of specific ≥ grade 2 skin toxicities over 12 weeks or until a value of 6-10 is observed on the VAS, whichever is sooner</measure>
    <time_frame>30 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to first occurrence of specific ≥ grade 2 skin toxicities</measure>
    <time_frame>30 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Most severe specific ≥ grade 3 skin toxicities of interest over 12 weeks or until a value of 6-10 is observed on the VAS, whichever is sooner</measure>
    <time_frame>30 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to the first most severe specific ≥ grade 3 skin toxicities</measure>
    <time_frame>30 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of panitumumab dose reduction due to the specific skin toxicities of interest over 12 weeks or until a value of 6-10 is observed on the VAS, whichever is sooner</measure>
    <time_frame>30 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Scores in DLQI under preemptive basic skin treatment with or without doxycycline</measure>
    <time_frame>30month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of doxycycline related adverse events</measure>
    <time_frame>30 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Type of panitumumab related adverse events</measure>
    <time_frame>30 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response rate to panitumumab over 12 weeks or until a value of 6-10 is observed on the VAS, whichever is sooner (only if patient received at least 8 weeks of study treatment)</measure>
    <time_frame>30 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Type of doxycycline related adverse events</measure>
    <time_frame>30 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Severity of doxycycline related adverse events</measure>
    <time_frame>30 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of panitumumab related adverse events</measure>
    <time_frame>30 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Severity of panitumumab related adverse events</measure>
    <time_frame>30 month</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">11</enrollment>
  <condition>Colorectal Carcinoma</condition>
  <arm_group>
    <arm_group_label>Doxycycline 100 mg BID oral use</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo 100 mg BID oral use</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Panitumumab, Doxycycline/Placebo</intervention_name>
    <description>comparison of Doxycyline/Placebo and Panitumumab regarding efficacy of the therapy of panitumumab induced skin toxicity</description>
    <arm_group_label>Doxycycline 100 mg BID oral use</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Panitumumab</intervention_name>
    <description>mCRC patients receiving panitumumab as EGFR inhibitor.</description>
    <arm_group_label>Placebo 100 mg BID oral use</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients with advanced or metastatic colorectal cancer (mCRC) and non-mutated
             (wild-type) KRAS who are planned to receive treatment with panitumumab monotherapy
             after failure of fluoropyrimidine-, oxaliplatin-, and irinotecan-containing
             chemotherapy regimens and without prior treatment with epidermal growth factor
             receptor (EGFR) antibody

          2. Man or woman 18 years of age or older

          3. Signed and dated informed consent before the start of specific protocol procedures

          4. ECOG (Eastern Cooperative Oncology Group) performance status of 0, 1, or 2

          5. Bilirubin ≤ 1.5 x ULN, SGOT/SGPT ≤ 2.5 x ULN, AP ≤ 3 x ULN if no evidence of liver
             metastases or Bilirubin ≤ 3 x ULN, SGOT/SGPT ≤ 5 x ULN, AP ≤ 5 x ULN if evidence of
             liver metastases

          6. Women of child-bearing potential have to use adequate highly effective methods of
             contraception . Since doxycyline may reduce efficacy of hormonal contraceptives, women
             of child-bearing potential have to use double-barrier methods within 4 weeks before
             first intake of study medication, during study participation and at least 6 weeks
             after last intake of study medication even if using hormonal contraceptives Women are
             considered to be of child-bearing potential unless they are ≥ 50 years old and for
             more than 2 years amenorrheic or unless they are surgically sterile.

        Exclusion Criteria:

          1. Absence of any of the above-listed inclusion criteria

          2. Any serious medical condition or psychiatric illness that would interfere with the
             patient's ability to sign the informed consent form.

          3. Allergic reaction to one of the medications to be used

          4. Subject allergic to panitumumab or any components of the panitumumab formulation or
             treatment regimen

          5. Prior treatment with EGFR antibody

          6. CYP3A4 enzyme inducers, inhibitors, and substrates (eg, phenytoin, phenobarbital,
             carbamazepine, ketoconazole, rifampicin, rifabutin, and St. John's Wort) ≤ 2 weeks
             before randomization (itraconazole should be used with caution)

          7. Subjects with hypersensitivity to doxycycline, other tetracyclines, or ingredients of
             doxycycline capsules

          8. Systemic treatment with antibiotics which was completed less than 7 days prior to
             randomization

          9. Pregnant and/or breast-feeding women

         10. Active participation in other clinical studies in the previous 4 weeks

         11. Serious liver function disorders

         12. History of, or evidence of, interstitial pneumonitis or pulmonary fibrosis

         13. Person who has been committed to an institution by virtue of an order issued either by
             the judicial or the administrative authorities.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hanno Riess, Prof.</last_name>
    <role>Study Chair</role>
    <affiliation>Charité Campus Virchow Klinikum, Klinik für Innere Medizin mit Schwerpunkt Hämatologie u. Onkologie</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>DRK Kliniken Berlin / Köpenick, Klinik für Chirurgie</name>
      <address>
        <city>Berlin</city>
        <zip>12559</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Onkologische Schwerpunktpraxis</name>
      <address>
        <city>Berlin</city>
        <zip>13055</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medizinisches Versorgungszentrum Ärzteforum Seestraße</name>
      <address>
        <city>Berlin</city>
        <zip>13347</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Charité Campus Virchow Klinikum (CVK), Centrum für Tumormedizin, Medizinische Klinik mit Schwerpunkt Hämatologie u. Onkologie</name>
      <address>
        <city>Berlin</city>
        <zip>13355</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ärzteforum Bernau</name>
      <address>
        <city>Bernau</city>
        <zip>16321</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Onkologische Schwerpunktpraxis</name>
      <address>
        <city>Brandenburg</city>
        <zip>14770</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Städtisches Klinikum Dessau, Hömatologie und Internistische Onkologie</name>
      <address>
        <city>Dessau</city>
        <zip>06847</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Georg Klinikum Eisenach gGmbH, Klinik für Innere Medizin 2</name>
      <address>
        <city>Eisenach</city>
        <zip>99817</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Krankenhaus St. Elisabeth u. St. Barbara, Klinik für Allgemein- u. Visceralchirurgie</name>
      <address>
        <city>Halle</city>
        <zip>06110</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ärzteforum Hennigsdorf</name>
      <address>
        <city>Hennigsdorf</city>
        <zip>16761</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>eps-early phase GmbH</name>
      <address>
        <city>Jena</city>
        <zip>07743</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Dorothea Christiane Erxleben Quedlinburg gGmbH, Klinik f. Allgemein, Vizeral- und Gefäßchirurgie</name>
      <address>
        <city>Quedlinburg</city>
        <zip>06484</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>March 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 3, 2011</study_first_submitted>
  <study_first_submitted_qc>August 16, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 17, 2011</study_first_posted>
  <last_update_submitted>July 11, 2014</last_update_submitted>
  <last_update_submitted_qc>July 11, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 14, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>skin toxicity</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Doxycycline</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

